

Lenvatinib CLEAR

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Early stopping or crossover



Lenvatinib CLEAR

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response


NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatment

Experimental Arm: Lenvatinib + Pembrolizumab

Control Arm: Sunitinib

